Background Oxymatrine has certain antiviral effects in the treatment of chronic hepatitis B （CHB）, but its exact mechanism is unclear. The objective of the present study was to explore oxymatrine＇s antiviral mechan...Background Oxymatrine has certain antiviral effects in the treatment of chronic hepatitis B （CHB）, but its exact mechanism is unclear. The objective of the present study was to explore oxymatrine＇s antiviral mechanism by studying its effect on the hepatitis B virus （HBV） specific cytotoxic T lymphocyte （CTL） surface programmed death receptor-1 （PD-1） expression in CHB patients. Methods Sixty-five CHB patients who had HBV DNA≥104 copies/mL positive HBeAg, positive human leukocyte antigen （HLA）-A2, alanine aminotransferase （ALT） 〉2xupper limit of normal value （ULN） were randomly divided into two groups： treatment group （n=33）, treated with an intravenous infusion of 600 mg oxymatrine in glucose solution once a day for a month, then with a 200 mg oxymatrine oral capsule three times a day, and a 200 mg silibin meglumine tablet three times a day; control group （n=32） patients were treated only with silibin meglumine tablet, method and dosage were the same as those of treatment group. Three months later, peripheral blood HBV-specific CTL surface PD-1 expression, HBV-specific CTL level, HBV DNA, HBeAg, and results of liver function tests were analyzed and compared. Results Three months post-treatment, in the treatment group, peripheral blood HBV-specific CTL surface PD-1 expression （（19.42±15.94）%） decreased significantly compared to the pretreatment level （（31.30±24.06）%; P 〈0.05）, and decreased significantly compared to that of control group three months after treatment （（29.45±21.62）%; P 〈0.05）. HBV-specific CTL level （（0.42±0.07）%） significantly increased compared with the pretreatment （（0.29±0.15）%; P 〈0.01）, and the control group posttreatment level was （0.31±0.15）% （P 〈0.05）. HBV DNA level in 11 cases became negative （HBV DNA〈500 copies/ml, 33.33%）, which was higher than that of the control group after treatment （two cases, 6.25%; X2=7.45, P 〈0.01）, HBeAg of nine cases turned negative （27.27%）展开更多
文摘Background Oxymatrine has certain antiviral effects in the treatment of chronic hepatitis B （CHB）, but its exact mechanism is unclear. The objective of the present study was to explore oxymatrine＇s antiviral mechanism by studying its effect on the hepatitis B virus （HBV） specific cytotoxic T lymphocyte （CTL） surface programmed death receptor-1 （PD-1） expression in CHB patients. Methods Sixty-five CHB patients who had HBV DNA≥104 copies/mL positive HBeAg, positive human leukocyte antigen （HLA）-A2, alanine aminotransferase （ALT） 〉2xupper limit of normal value （ULN） were randomly divided into two groups： treatment group （n=33）, treated with an intravenous infusion of 600 mg oxymatrine in glucose solution once a day for a month, then with a 200 mg oxymatrine oral capsule three times a day, and a 200 mg silibin meglumine tablet three times a day; control group （n=32） patients were treated only with silibin meglumine tablet, method and dosage were the same as those of treatment group. Three months later, peripheral blood HBV-specific CTL surface PD-1 expression, HBV-specific CTL level, HBV DNA, HBeAg, and results of liver function tests were analyzed and compared. Results Three months post-treatment, in the treatment group, peripheral blood HBV-specific CTL surface PD-1 expression （（19.42±15.94）%） decreased significantly compared to the pretreatment level （（31.30±24.06）%; P 〈0.05）, and decreased significantly compared to that of control group three months after treatment （（29.45±21.62）%; P 〈0.05）. HBV-specific CTL level （（0.42±0.07）%） significantly increased compared with the pretreatment （（0.29±0.15）%; P 〈0.01）, and the control group posttreatment level was （0.31±0.15）% （P 〈0.05）. HBV DNA level in 11 cases became negative （HBV DNA〈500 copies/ml, 33.33%）, which was higher than that of the control group after treatment （two cases, 6.25%; X2=7.45, P 〈0.01）, HBeAg of nine cases turned negative （27.27%）
